Intersection · Pharmacology × semaglutide
Pharmacology topics tagged semaglutide
Topics in Pharmacology carrying the tag semaglutide. GLP-1 receptor agonist; the compound with the largest published human dataset in this class.
29 topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Receptor desensitisation as a tolerance hypothesis, and its weak evidence
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a…
|
+52 | 57 | 25k | just now |
|
GLP-1 receptor distribution: central and peripheral
Posting this under the heading it deserves: GLP-1 receptor distribution: central and peripheral Everything below is what sits behind that. A documentation question rather than an analytical one. I have a…
|
+90 | 98 | 30k | 22h |
|
Peak-to-trough ratio at steady state for a weekly agent — the long version
Peak-to-trough ratio at steady state for a weekly agent — the long version Writing it up because I had to work it out twice and would rather nobody else did. I would like to understand what this number means…
|
+57 | 61 | 708 | 1d |
|
Coming back to: Time to steady state after a dose increase
Time to steady state after a dose increase Writing it up because I had to work it out twice and would rather nobody else did. Posting the method first, because I know what the first three replies will…
|
+104 | 110 | 16k | 2d |
|
About the Receptor biology category
GLP-1, GIP, glucagon and amylin receptor signalling, bias, desensitisation and central versus peripheral action. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit…
|
+6 | 10 | 34k | 20d |
|
Peak-to-trough ratio at steady state for a weekly agent
On the subject in the title: Peak-to-trough ratio at steady state for a weekly agent Working notes rather than a conclusion. I would like to understand what this number means before I repeat it anywhere. A…
|
+58 | 64 | 9.7k | 2mo |
|
Clearance pathways and what renal impairment changes
Clearance pathways and what renal impairment changes Writing it up because I had to work it out twice and would rather nobody else did. I would like to understand what this number means before I repeat it…
|
+11 | 15 | 43k | 2mo |
|
Coming back to: Washout: how long is long enough, and for what purpose
Posting this under the heading it deserves: Washout: how long is long enough, and for what purpose Everything below is what sits behind that. Working through the identity arithmetic and I would like it…
|
+128 | 139 | 3k | 3mo |
|
GLP-1 receptor distribution: central and peripheral — one year on
GLP-1 receptor distribution: central and peripheral — one year on — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a…
|
+7 | 11 | 43k | 3mo |
|
Coming back to: Half-life, steady state, and accumulation worked through
On the subject in the title: Half-life, steady state, and accumulation worked through Working notes rather than a conclusion. Working through the identity arithmetic and I would like it checked. semaglutide…
|
+14 | 18 | 15k | 3mo |
|
Half-life, steady state, and accumulation worked through — a second dataset
Half-life, steady state, and accumulation worked through — a second dataset — setting out what I have, and where I think it stops being reliable. Working through the identity arithmetic and I would like it…
|
+110 | 126 | 14k | 4mo |
|
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version
Posting this under the heading it deserves: Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version Everything below is what sits behind that. I would like to understand…
|
+57 | 63 | 1k | 6mo |
|
Follow-up: Glucagon receptor agonism in a weight-loss compound
Glucagon receptor agonism in a weight-loss compound Writing it up because I had to work it out twice and would rather nobody else did. I would like to understand what this number means before I repeat it…
|
+5 | 9 | 21k | 7mo |
|
About the Pharmacokinetics category
Half-life, accumulation, steady state, albumin binding, and why weekly dosing works. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
|
4 | 32k | 8mo | |
|
Follow-up: Why appetite effects are mostly central
Asking directly, because I could not find a straight answer: Why appetite effects are mostly central A documentation question rather than an analytical one. I have a certificate in front of me that reports a…
|
+86 | 90 | 61k | 9mo |
|
Amylin receptor signalling and satiety
Amylin receptor signalling and satiety Writing it up because I had to work it out twice and would rather nobody else did. A documentation question rather than an analytical one. I have a certificate in front…
|
+22 | 26 | 1.8k | 9mo |
|
Follow-up: Subcutaneous absorption kinetics and site differences
Subcutaneous absorption kinetics and site differences — setting out what I have, and where I think it stops being reliable. I would like to understand what this number means before I repeat it anywhere. A…
|
4 | 9.9k | 10mo | |
|
Washout: how long is long enough, and for what purpose
Washout: how long is long enough, and for what purpose — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a certificate in…
|
+63 | 70 | 13k | 10mo |
|
GIP receptor agonism and the argument about direction
GIP receptor agonism and the argument about direction — setting out what I have, and where I think it stops being reliable. Posting the method first, because I know what the first three replies will otherwise…
|
2 | 867 | 10mo | |
|
Vagal afferents and the gut-brain pathway — one year on
Vagal afferents and the gut-brain pathway — one year on Writing it up because I had to work it out twice and would rather nobody else did. A documentation question rather than an analytical one. I have a…
|
2 | 136 | 11mo | |
|
Subcutaneous absorption kinetics and site differences
Posting this under the heading it deserves: Subcutaneous absorption kinetics and site differences Everything below is what sits behind that. I would like to understand what this number means before I repeat…
|
+15 | 19 | 3.9k | 12mo |
|
Vagal afferents and the gut-brain pathway
On the subject in the title: Vagal afferents and the gut-brain pathway Working notes rather than a conclusion. A documentation question rather than an analytical one. I have a certificate in front of me that…
|
+5 | 9 | 44k | 13mo |
|
Half-life, steady state, and accumulation worked through
Half-life, steady state, and accumulation worked through Writing it up because I had to work it out twice and would rather nobody else did. Working through the identity arithmetic and I would like it checked.…
|
+115 | 130 | 44k | 13mo |
|
Albumin binding and how it produces a long half-life
Albumin binding and how it produces a long half-life — setting out what I have, and where I think it stops being reliable. I would like to understand what this number means before I repeat it anywhere. A…
|
+38 | 44 | 6.6k | 14mo |
|
Why appetite effects are mostly central
Why appetite effects are mostly central I have a specific reason for asking rather than idle curiosity, and the context is below. Posting the method first, because I know what the first three replies will…
|
2 | 56k | 16mo | |
|
Biased agonism: a real phenomenon, an over-used explanation
Posting this under the heading it deserves: Biased agonism: a real phenomenon, an over-used explanation Everything below is what sits behind that. A documentation question rather than an analytical one. I…
|
+130 | 135 | 23k | 16mo |
|
Second pass at: Albumin binding and how it produces a long half-life
Posting this under the heading it deserves: Second pass at: Albumin binding and how it produces a long half-life Everything below is what sits behind that. I would like to understand what this number means…
|
+7 | 11 | 31k | 17mo |
|
Glucagon receptor agonism in a weight-loss compound
On the subject in the title: Glucagon receptor agonism in a weight-loss compound Working notes rather than a conclusion. Posting the method first, because I know what the first three replies will otherwise…
|
2 | 5.1k | 20mo | |
|
Time to steady state after a dose increase
On the subject in the title: Time to steady state after a dose increase Working notes rather than a conclusion. A documentation question rather than an analytical one. I have a certificate in front of me that…
|
+151 | 163 | 9.7k | 21mo |